Log in

MediGene Stock Forecast, Price & News

+0.07 (+1.54 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: €4.62
50-Day Range
MA: €4.92
52-Week Range
Now: €4.62
Volume8,975 shs
Average Volume306,207 shs
Market Capitalization$113.48 million
P/E RatioN/A
Dividend YieldN/A
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.
Read More
MediGene logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$8.57 million
Cash Flow€1.62 per share
Book Value€2.82 per share



Market Cap$113.48 million
Next Earnings DateN/A
OptionableNot Optionable
+0.07 (+1.54 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MediGene (ETR:MDG1) Frequently Asked Questions

How has MediGene's stock price been impacted by Coronavirus?

MediGene's stock was trading at €4.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDG1 shares have increased by 11.2% and is now trading at €4.62.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of MediGene?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for MediGene

What price target have analysts set for MDG1?

1 equities research analysts have issued 1 year target prices for MediGene's stock. Their forecasts range from €11.00 to €11.00. On average, they anticipate MediGene's stock price to reach €11.00 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for MediGene

Who are some of MediGene's key competitors?

What other stocks do shareholders of MediGene own?

Who are MediGene's key executives?

MediGene's management team includes the following people:
  • Dr. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)
  • Dr. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management Board
  • Dr. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)
  • Mr. Axel-Sven Malkomes, CFO, Chief Bus. Devel. Officer and Member of Exec. Management Board
  • Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

What is MediGene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €4.62.

How big of a company is MediGene?

MediGene has a market capitalization of $113.48 million and generates $8.57 million in revenue each year. MediGene employs 106 workers across the globe.

What is MediGene's official website?

The official website for MediGene is www.medigene.de.

How can I contact MediGene?

MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.